KMT2A and acute myeloid leukemia: In addition to the targeted drugs discussed above, several promising novel agents are under way for AML treatment including inhibitors of epigenetic BET regulators [bromodomain (BRD) and extraterminal (BET) proteins], disrupters of telomeric silencing 1-like (DOT1L) and lysine specific demethylase (LSD1), as well as a KMT2A-menin- inhibitors.